What Researchers Did
Researchers conducted a prospective observational study to investigate changes in serum nitric oxide (NO) and endothelin-1 (ET-1) levels in 64 patients with peripheral arterial disease undergoing hyperbaric oxygen therapy (HBOT).
What They Found
Serum nitric oxide (NO) levels did not significantly change after hyperbaric oxygen therapy (HBOT) in most patients, except for a significant increase in those with stage II peripheral arterial disease (21.9 vs. 26.2, p=0.04). Conversely, endothelin-1 (ET-1) levels significantly increased in all studied patients after HBOT (4.2 vs. 18.3, p<0.001). This suggests HBOT may lead to a predominance of vasoconstrictor effects.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor does it involve Canadian researchers or specific Canadian health policies.
Study Limitations
The study's observational design and the need to consider other interfering factors, such as exposure time and antioxidant activation, limit the interpretation of nitric oxide effects.